A Study of PLX73086 in Advanced Solid Tumors and Locally Advanced or Refractory Tenosynovial Giant Cell Tumor
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).
Solid Tumors|Tenosynovial Giant Cell Tumor|Synovitis, Pigmented Villonodular
DRUG: PLX73086
Safety of PLX73086, as measured by adverse events and serious adverse events [Part 1 and Part 2 of research study], 1 year|Area under the concentration-time curve (AUC) of PLX73086 [Part 1 of research study], 1 year|Maximum observed concentration (Cmax) of PLX73086 [Part 1 of research study], 1 year|Time to peak concentration (Tmax) of PLX73086 [Part 1 of research study], 1 year|Half life (t1/2) of PLX73086 [Part 1 of research study], 1 year
Efficacy of PLX73086 measured by overall response rate (ORR) [Part 1 of research study], 1 year
The purpose of this research study is to evaluate safety, pharmacokinetics and preliminary efficacy of the investigational drug PLX73086 in subjects with solid tumors including subjects with locally advanced or refractory tenosynovial giant cell tumor (TGCT).